SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Why You Should Play the Reflation Trade: Stock Picker

MORE HEADLINES

» Markets | Economy | Companies

- Half of Banks' Losses May Still Be Hidden: IMF Head

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Jan.12

1:35 PM ET

Monday, 12 Jan 2009

Is Roche In A Rush For Genentech?

Posted By:Mike Huckman

Topics:Stock Market | Medicine | Corporate News | CEOs and CFOs | Pharmaceuticals

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:JPMorgan Chase and Co | Genentech, Inc. | Pfizer Inc

Roche CFO's presentation at the JPMorgan Healthcare Conference
CNBC.com
Roche CFO's presentation at the JPMorgan Healthcare Conference
Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference[JPM Loading... () ] .

You'd expect high interest after the "Financial Times" reported last Friday afternoon that the Swiss drugmaker is going to up its bid for Genentech.

Roche CFO Erich Hunziker didn't talk about that. But he did say, "We see very clearly that we will not touch innovation (at Genentech), but there's a lot of synergies we can win in this market."

He acknowledged the "fear" that Roche will "destroy" Genentech [DNA Loading... () ] , especially here in the Bay Area where DNA is headquartered, but Hunziker said, "The cuts we will do at the Roche side are much tougher that what we will do at the Genentech side."

Overflow crowd at breakout roche session
CNBC.com
Overflow crowd at breakout roche session
The crowd for the Roche breakout session where the q and a takes place was so big I couldn't get in.

I found it curious that there were three bylines (reporter names) on the FT story, but no attribution whatsoever. No "a source familiar with the situation" or "according to people who are close to the negotiations," etc. I could never go on air without attributing that kind of information even to an anonymous source.

Anyway, Genentech CEO Art Levinson presents tomorrow at 5:30 ET. The company reports earnings after the closing bell this Thursday, so don't expect him to say much here tomorrow. Like Roche, Genentech has been pretty tight-lipped about all this.

At the time of DNA's presentation I will be on "Fast Money" for a live interview with athenahealth CEO Jonathan Bush. ATHN [ATHN Loading... () ] is an electronic medical records company that hopes to benefit from President-elect Obama's plan to digitize all the doctors' paperwork.